tradingkey.logo
搜索

Harvard Bioscience Inc

HBIO
添加自选
6.100USD
+0.010+0.16%
收盘 07-31 16:00美东报价延迟15分钟
27.51M总市值
亏损市盈率 TTM

关于 Harvard Bioscience Inc 公司

Harvard Bioscience, Inc. is a developer, manufacturer and seller of technologies, products and services that enable fundamental advances in life science applications, including research, drug and therapy discovery, bio-production and preclinical testing for pharmaceutical and therapy development. The Company’s products and services are sold globally to customers ranging from renowned academic institutions and government laboratories to pharmaceutical, biotechnology and contract research organizations (CROs). Its two product categories are cellular and molecular technology (CMT) and Preclinical. Its CMT product family includes the Harvard Apparatus, Biochrom, BTX, HEKA, KD Scientific, MCS and Warner brands. Its Preclinical product family provides a complete platform to assess physiological data from organisms for research ranging from basic research to drug discovery, and drug development services. The Preclinical Product family includes the DSI, Panlab, Hugo Sachs and Buxco brands.

Harvard Bioscience Inc简介

公司代码HBIO
公司名称Harvard Bioscience Inc
上市日期Oct 21, 2013
CEODuke (John D)
员工数量330
证券类型Ordinary Share
年结日Oct 21
公司地址84 October Hill Rd
城市HOLLISTON
上市交易所NASDAQ OMX - NASDAQ BASIC
国家United States of America
邮编01746-1371
电话15088938999
网址https://www.harvardbioscience.com/
公司代码HBIO
上市日期Oct 21, 2013
CEODuke (John D)

Harvard Bioscience Inc公司高管

名称
名称/职务
职务
持股
持股变动
Ms. Katherine Anne Eade, J.D.
Ms. Katherine Anne Eade, J.D.
Lead Independent Director
Lead Independent Director
58.67K
+28.22%
Mr. Robert E. (Rob) Gagnon
Mr. Robert E. (Rob) Gagnon
Independent Director
Independent Director
27.56K
+60.08%
Mr. Stephen J. DeNelsky
Mr. Stephen J. DeNelsky
Director
Director
26.56K
+62.34%
Mr. Robert Benson
Mr. Robert Benson
Independent Director
Independent Director
--
--
Mr. Sandy Martin
Mr. Sandy Martin
Investor Relations
Investor Relations
--
--
Mr. Mark Frost
Mr. Mark Frost
Interim Chief Financial Officer, Treasurer
Interim Chief Financial Officer, Treasurer
--
--
Mr. John D. Duke
Mr. John D. Duke
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
名称
名称/职务
职务
持股
持股变动
Ms. Katherine Anne Eade, J.D.
Ms. Katherine Anne Eade, J.D.
Lead Independent Director
Lead Independent Director
58.67K
+28.22%
Mr. Robert E. (Rob) Gagnon
Mr. Robert E. (Rob) Gagnon
Independent Director
Independent Director
27.56K
+60.08%
Mr. Stephen J. DeNelsky
Mr. Stephen J. DeNelsky
Director
Director
26.56K
+62.34%
Mr. Robert Benson
Mr. Robert Benson
Independent Director
Independent Director
--
--
Mr. Sandy Martin
Mr. Sandy Martin
Investor Relations
Investor Relations
--
--
Mr. Mark Frost
Mr. Mark Frost
Interim Chief Financial Officer, Treasurer
Interim Chief Financial Officer, Treasurer
--
--

常见问题

Harvard Bioscience Inc的前五大股东是谁?

Harvard Bioscience Inc 的前五大股东如下:Ms. Katherine Anne Eade, J.D.

有多少机构持有Harvard Bioscience Inc(HBIO)的股份?

截至2026Q1,共有201家机构持有Harvard Bioscience Inc的股份,合计持有的股份价值约为2.44M,占公司总股份的54.17%。与2025Q4相比,机构持股有所增加,增幅为-447956.00。

哪个业务部门对Harvard Bioscience Inc的收入贡献最大?

在2026Q1,Instruments, equipment, software and accessories业务部门对Harvard Bioscience Inc的收入贡献最大,创收78.26M,占总收入的90.42%。
tradingkey.logo
风险提示:我们的网站和移动应用程序仅提供关于某些投资产品的一般信息。Finsights 不提供财务建议或对任何投资产品的推荐,且提供此类信息不应被解释为 Finsights 提供财务建议或推荐。
投资产品存在重大投资风险,包括可能损失投资的本金,且可能并不适合所有人。投资产品的过去表现并不代表其未来表现。
Finsights 可能允许第三方广告商或关联公司在我们的网站或移动应用程序的任何部分放置或投放广告,并可能根据您与广告的互动情况获得报酬。
© 版权所有: FINSIGHTS MEDIA PTE. LTD. 版权所有